Home > Publications database > Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. > print

001     167147
005     20240229123234.0
024 7 _ |a 10.1158/1055-9965.EPI-20-0651
|2 doi
024 7 _ |a pmid:32967863
|2 pmid
024 7 _ |a pmc:PMC7710600
|2 pmc
024 7 _ |a 1055-9965
|2 ISSN
024 7 _ |a 1538-7755
|2 ISSN
024 7 _ |a altmetric:91198382
|2 altmetric
037 _ _ |a DKFZ-2021-00166
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Ghoneim, Dalia H
|b 0
245 _ _ |a Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk.
260 _ _ |a Philadelphia, Pa.
|c 2020
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1614689817_29318
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Whether circulating polyunsaturated fatty acid (PUFA) levels are associated with pancreatic cancer risk is uncertain. Mendelian randomization (MR) represents a study design using genetic instruments to better characterize the relationship between exposure and outcome.We utilized data from genome-wide association studies within the Pancreatic Cancer Cohort Consortium and Pancreatic Cancer Case-Control Consortium, involving approximately 9,269 cases and 12,530 controls of European descent, to evaluate associations between pancreatic cancer risk and genetically predicted plasma n-6 PUFA levels. Conventional MR analyses were performed using individual-level and summary-level data.Using genetic instruments, we did not find evidence of associations between genetically predicted plasma n-6 PUFA levels and pancreatic cancer risk [estimates per one SD increase in each PUFA-specific weighted genetic score using summary statistics: linoleic acid odds ratio (OR) = 1.00, 95% confidence interval (CI) = 0.98-1.02; arachidonic acid OR = 1.00, 95% CI = 0.99-1.01; and dihomo-gamma-linolenic acid OR = 0.95, 95% CI = 0.87-1.02]. The OR estimates remained virtually unchanged after adjustment for covariates, using individual-level data or summary statistics, or stratification by age and sex.Our results suggest that variations of genetically determined plasma n-6 PUFA levels are not associated with pancreatic cancer risk.These results suggest that modifying n-6 PUFA levels through food sources or supplementation may not influence risk of pancreatic cancer.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Zhu, Jingjing
|b 1
700 1 _ |a Zheng, Wei
|b 2
700 1 _ |a Long, Jirong
|b 3
700 1 _ |a Murff, Harvey J
|b 4
700 1 _ |a Ye, Fei
|b 5
700 1 _ |a Setiawan, Veronica Wendy
|b 6
700 1 _ |a Wilkens, Lynne R
|b 7
700 1 _ |a Khankari, Nikhil K
|b 8
700 1 _ |a Haycock, Philip
|0 0000-0001-5001-3350
|b 9
700 1 _ |a Antwi, Samuel O
|b 10
700 1 _ |a Yang, Yaohua
|b 11
700 1 _ |a Arslan, Alan A
|0 0000-0002-7775-8085
|b 12
700 1 _ |a Beane Freeman, Laura E
|b 13
700 1 _ |a Bracci, Paige M
|b 14
700 1 _ |a Canzian, Federico
|0 P:(DE-He78)5323704270b6393dcea70186ffd86bca
|b 15
700 1 _ |a Du, Mengmeng
|b 16
700 1 _ |a Gallinger, Steven
|b 17
700 1 _ |a Giles, Graham G
|0 0000-0003-4946-9099
|b 18
700 1 _ |a Goodman, Phyllis J
|b 19
700 1 _ |a Kooperberg, Charles
|b 20
700 1 _ |a Le Marchand, Loïc
|b 21
700 1 _ |a Neale, Rachel E
|b 22
700 1 _ |a Scelo, Ghislaine
|b 23
700 1 _ |a Visvanathan, Kala
|0 0000-0002-0582-8005
|b 24
700 1 _ |a White, Emily
|b 25
700 1 _ |a Albanes, Demetrius
|b 26
700 1 _ |a Amiano, Pilar
|b 27
700 1 _ |a Andreotti, Gabriella
|b 28
700 1 _ |a Babic, Ana
|b 29
700 1 _ |a Bamlet, William R
|0 0000-0003-2903-1284
|b 30
700 1 _ |a Berndt, Sonja I
|b 31
700 1 _ |a Brais, Lauren K
|b 32
700 1 _ |a Brennan, Paul
|0 0000-0002-0518-8714
|b 33
700 1 _ |a Bueno-de-Mesquita, Bas
|b 34
700 1 _ |a Buring, Julie E
|b 35
700 1 _ |a Campbell, Peter T
|b 36
700 1 _ |a Rabe, Kari G
|0 0000-0002-7313-1875
|b 37
700 1 _ |a Chanock, Stephen J
|b 38
700 1 _ |a Duggal, Priya
|b 39
700 1 _ |a Fuchs, Charles S
|b 40
700 1 _ |a Gaziano, J Michael
|b 41
700 1 _ |a Goggins, Michael G
|b 42
700 1 _ |a Hackert, Thilo
|0 0000-0002-7012-1196
|b 43
700 1 _ |a Hassan, Manal M
|b 44
700 1 _ |a Helzlsouer, Kathy J
|b 45
700 1 _ |a Holly, Elizabeth A
|b 46
700 1 _ |a Hoover, Robert N
|b 47
700 1 _ |a Katske, Verena
|0 0000-0002-6509-6555
|b 48
700 1 _ |a Kurtz, Robert C
|b 49
700 1 _ |a Lee, I-Min
|b 50
700 1 _ |a Malats, Núria
|0 0000-0003-2538-3784
|b 51
700 1 _ |a Milne, Roger L
|0 0000-0001-5764-7268
|b 52
700 1 _ |a Murphy, Neil
|b 53
700 1 _ |a Oberg, Ann L
|0 0000-0003-2539-9807
|b 54
700 1 _ |a Porta, Miquel
|b 55
700 1 _ |a Rothman, Nathaniel
|b 56
700 1 _ |a Sesso, Howard D
|0 0000-0002-9698-9954
|b 57
700 1 _ |a Silverman, Debra T
|b 58
700 1 _ |a Thompson, Ian M
|b 59
700 1 _ |a Wactawski-Wende, Jean
|0 0000-0003-3096-9595
|b 60
700 1 _ |a Wang, Xiaoliang
|b 61
700 1 _ |a Wentzensen, Nicolas
|b 62
700 1 _ |a Yu, Herbert
|0 0000-0003-3950-4815
|b 63
700 1 _ |a Zeleniuch-Jacquotte, Anne
|b 64
700 1 _ |a Yu, Kai
|0 0000-0003-3950-4815
|b 65
700 1 _ |a Wolpin, Brian M
|b 66
700 1 _ |a Jacobs, Eric J
|0 0000-0001-5256-0163
|b 67
700 1 _ |a Duell, Eric J
|b 68
700 1 _ |a Risch, Harvey A
|b 69
700 1 _ |a Petersen, Gloria M
|b 70
700 1 _ |a Amundadottir, Laufey T
|0 0000-0003-1859-8971
|b 71
700 1 _ |a Kraft, Peter
|b 72
700 1 _ |a Klein, Alison P
|0 0000-0003-2737-8399
|b 73
700 1 _ |a Stolzenberg-Solomon, Rachel Z
|b 74
700 1 _ |a Shu, Xiao-Ou
|b 75
700 1 _ |a Wu, Lang
|b 76
773 _ _ |a 10.1158/1055-9965.EPI-20-0651
|g Vol. 29, no. 12, p. 2735 - 2739
|0 PERI:(DE-600)2036781-8
|n 12
|p 2735 - 2739
|t Cancer epidemiology, biomarkers & prevention
|v 29
|y 2020
|x 1538-7755
909 C O |p VDB
|o oai:inrepo02.dkfz.de:167147
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)5323704270b6393dcea70186ffd86bca
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 48
|6 0000-0002-6509-6555
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
913 2 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2020
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER EPIDEM BIOMAR : 2018
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-09-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-09-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-09-04
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCER EPIDEM BIOMAR : 2018
|d 2020-09-04
920 1 _ |0 I:(DE-He78)C055-20160331
|k C055
|l C055 Genomische Epidemiologie
|x 0
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C055-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21